
Metformin (500mg) + Voglibose (0.2mg) + Glimepiride (1mg)
Active composition
+2 more active ingredients
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
Medical applications
Metsmall GV 1 Tablet SR is a novel oral antidiabetic combination product containing glimepiride, metformin, and voglibose. This once-daily, controlled-release tablet is designed to provide sustained therapeutic activity over an extended period. Glimepiride, a sulfonylurea, stimulates insulin secretion, while metformin, a biguanide, enhances insulin sensitivity and reduces glucose production in the liver. Voglibose, a alpha-glucosidase inhibitor, slows carbohydrate absorption in the gut. Together, these agents synergistically address the multifactorial nature of type 2 diabetes, targeting both insulin resistance and insulin deficiency. The slow-release formulation allows for a gradual increase in plasma concentrations, providing a consistent therapeutic effect throughout the day. Metsmall GV 1 Tablet SR is indicated for the treatment of type 2 diabetes mellitus in adults, particularly those who are inadequately controlled with monotherapy or as an adjunct to diet and exercise.
How to use Metsmall GV Tablet SR Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Metsmall GV 1 Tablet SR is to be taken with food.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
It is unsafe to consume alcohol with Metsmall GV 1 Tablet SR.
High Risk
Metsmall GV 1 Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Metsmall GV 1 Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Metsmall GV 1 Tablet SR may be needed. Please consult your doctor. Metsmall GV 1 Tablet SR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
Regular Checkup
Metsmall GV 1 Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Metsmall GV 1 Tablet SR is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Metsmall GV 1 Tablet SR is, however, not recommended in patients with severe kidney disease.
Regular Checkup
0 reviews for Metsmall GV 1 Tablet SR

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
Medical applications
Metsmall GV 1 Tablet SR is a novel oral antidiabetic combination product containing glimepiride, metformin, and voglibose. This once-daily, controlled-release tablet is designed to provide sustained therapeutic activity over an extended period. Glimepiride, a sulfonylurea, stimulates insulin secretion, while metformin, a biguanide, enhances insulin sensitivity and reduces glucose production in the liver. Voglibose, a alpha-glucosidase inhibitor, slows carbohydrate absorption in the gut. Together, these agents synergistically address the multifactorial nature of type 2 diabetes, targeting both insulin resistance and insulin deficiency. The slow-release formulation allows for a gradual increase in plasma concentrations, providing a consistent therapeutic effect throughout the day. Metsmall GV 1 Tablet SR is indicated for the treatment of type 2 diabetes mellitus in adults, particularly those who are inadequately controlled with monotherapy or as an adjunct to diet and exercise.
How to use Metsmall GV Tablet SR Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Metsmall GV 1 Tablet SR is to be taken with food.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
It is unsafe to consume alcohol with Metsmall GV 1 Tablet SR.
High Risk
Metsmall GV 1 Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Metsmall GV 1 Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Metsmall GV 1 Tablet SR may be needed. Please consult your doctor. Metsmall GV 1 Tablet SR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
Regular Checkup
Metsmall GV 1 Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Metsmall GV 1 Tablet SR is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Metsmall GV 1 Tablet SR is, however, not recommended in patients with severe kidney disease.
Regular Checkup
0 reviews for Metsmall GV 1 Tablet SR













